跳至主要内容
临床试验/NCT00502853
NCT00502853已完成4 期

Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.

Hoffmann-La Roche1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2007年10月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
10
试验地点
1
主要终点
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score

研究概览

简要总结

This single arm study will measure the effect of MabThera in combination with methotrexate on the progression of synovitis, the extent of bone marrow edema, and the number of erosions in the wrist and hand of patients with rheumatoid arthritis, using a new MRI technique. Patients will receive MabThera 1000mg i.v. on days 1 and 15, in combination with a stable dosage of 10-25mg/week methotrexate throughout the duration of the study. Further courses of MabThera will be provided to eligible patients. MRI will be performed 1-2 weeks before treatment initiation, and repeated 1 and 6 months after the first MabThera infusion. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=3 months and <=10 years;
  • inadequate response to methotrexate (12.5-25mg/week) for >=3 months;
  • evidence of erosive disease and/or clinical synovitis in a signal joint.

排除标准

  • autoimmune rheumatic diseases other than RA;
  • surgical operations on bones/joints in 12 weeks prior to baseline visit;
  • concomitant treatment with biologic agents;
  • previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.

研究组 & 干预措施

1

Experimental

干预措施: rituximab [MabThera/Rituxan] (Drug)

1

Experimental

干预措施: Methotrexate (Drug)

结局指标

主要结局

Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score

时间窗: Baseline, Week 4, and Week 24

Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

OMERACT RAMRIS Bone Edema Score

时间窗: Baseline, Weeks 4 and 24

Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.

OMERACT RAMRIS Erosion Score

时间窗: Baseline, Week 4, and Week 24

MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.

Early Enhancement Rate (REE)

时间窗: Baseline, Weeks 4 and 24

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its "steady state" condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.

Relative Enhancement (RE) Score

时间窗: Baseline, Weeks 4 and 24

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its "steady state" condition (RE).

次要结局

  • Ritchie Articular Index Scores(Baseline and Weeks 4, 12, and 24)
  • Health Assessment Questionnaire - Disability Index (HAQ-DI) Score(Baseline and Weeks 4, 12, and 24)
  • Patient's Global Assessment of Pain(Baseline and Weeks 4, 12, and 24)
  • DAS28 Score(Baseline and Weeks 4, 12, and 24)
  • Erythrocyte Sedimentation Rate (ESR)(Baseline and Weeks 4, 12, and 24)
  • C-Reactive Protein (CRP)(Baseline and Weeks 4, 12, and 24)
  • Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count(Baseline and Weeks 4, 12, and 24)
  • Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations(Baseline and Weeks 4, 12, and 24)
  • Total Immunoglobulin (Ig) Concentrations(Baseline and Weeks 4, 12, and 24)
  • Hematocrit Concentration (%)(Baseline and Weeks 4, 12, and 24)
  • Percentage of Total B-lymphocytes(Baseline and Weeks 4, 12, and 24)
  • Erosion Score - Right Hand(Baseline and Week 24)
  • Erosion Score - Left Hand(Baseline and Week 24)
  • Joint Space Narrowing - Right Hand(Baseline and Week 24)
  • Joint Space Narrowing - Left Hand(Baseline and Week 24)
  • X-Rays: Right Hand Total Score(Baseline and Week 24)
  • X-Rays: Left Hand Total Score(Baseline and Week 24)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验